Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

27 results
Display

A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea

Shim J, On YK, Kwon SU, Nam GB, Lee MH, Park HW, Hong KS, Kim NH, Amarenco P, Rha SW, Shin DG, Rha JH, Kim YH

Background/Aims: Atrial fibrillation (AF)-related stroke accounts for 20% of ischemic strokes. Rivaroxaban use in AF patients for preventing stroke and systemic embolism was approved in 2013 in Korea. This study...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers

Lee JH, Lee JH, Jo KW, Huh JW, Oh YM, Lee JS

Objectives: Two randomized, controlled studies comparing outcomes in patients treated with direct oral anticoagulants or low-molecular weight heparin for cancer-associated venous thromboembolism (VTE) have previously been performed. However, gynecologic cancers...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)

Kim H, Lee YS, Kim TH, Cha MJ, Lee JM, Park J, Park JK, Kang KW, Shim J, Uhm JS, Park HW, Choi EK, Kim JB, Kim C, Kim J, Joung B

Background/Aims: Efforts to reduce stroke in patients with atrial fibrillation (AF) have focused on increasing physician adherence to oral anticoagulant (OAC) guidelines; however, the high early discontinuation rate of vitamin...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial

Yhim HY, Choi WI, Kim SH, Nam SH, Kim KH, Mun YC, Oh D, Hwang HG, Lee KW, Song EK, Kwon YS, Bang SM

BACKGROUND/AIMS: Limited data are available regarding the efficacy of rivaroxaban for the treatment of cancer-associated venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Is the Oral Chemical Prophylaxis Necessary for the Prevention of Venous Thromboembolism after Joint Arthroplasty in a Korean Population?

Moon KH, Kang JS, Youn YH

PURPOSE: Venous thromboembolism (VTE) is a serious complication that may occur after a major orthopedic surgery. The aim of the present study was to determine the necessity of a chemical...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer

Lee JH, Oh YM, Lee SD, Lee JS

BACKGROUND: Low-molecular-weight heparin (LMWH) is the standard treatment for venous thromboembolism (VTE) in patients with active cancer. However, use of factor Xa inhibitors, such as rivaroxaban, is increasing on the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Kim H, Kim H, Cho SK, Kim JB, Joung B, Kim C

BACKGROUND AND OBJECTIVES: Rivaroxaban is noninferior to warfarin for preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate of intracranial...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Study on the Efficacy and Safety of Rivaroxaban in Urologic Cancer-Associated Venous Thromboembolism

Lee JH, You D, Lee SD, Oh YM, Lee JS

PURPOSE: Although direct oral anticoagulants (DOACs) are recommended as an alternative to low-molecular weighted heparin for cancer-associated venous thromboembolism (VTE), there is no firm evidence on the efficacy and safety...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real World Comparison of Rivaroxaban and Warfarin in Korean Patients with Atrial Fibrillation: Propensity Matching Cohort Analysis

Jeong HK, Lee KH, Park HW, Yoon NS, Kim MC, Lee N, Kim JS, Ahn Y, Jeong MH, Park JC, Cho JG

Rivaroxaban has emerged as a potential alternative to warfarin for the prevention of thromboembolism in patients with atrial fibrillation (AF). However, there has been concern for the risk of major...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes

Steiner T, Köhrmann , Schellinger PD, Tsivgoulis G

Oral anticoagulant-associated intracerebral hemorrhage (OAC-ICH) accounts for nearly 20% of all ICH. The number of patients with an indication for oral anticoagulant therapy (OAT) increases with increasing age. OAT became...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rivaroxaban and Acetylsalicylic Acid for Prevention of Venous Thromboembolism Following Total Knee Arthroplasty in Korean Patients

Chung KS, Shin TY, Park SH, Kim H, Choi CH

PURPOSE: To investigate the incidence of venous thromboembolism (VTE) after total knee arthroplasty (TKA) with chemoprophylaxis using acetylsalicylic acid (AA) or rivaroxaban in Korean patients. MATERIALS AND METHODS: Between May 2011...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation

Patel MR, Peacock WF, Tamayo S, Sicignano , Hopf KP, Yuan Z

OBJECTIVE: Patients with nonvalvular atrial fibrillation (AF) and renal disease (RD) who receive anticoagulation therapy appear to be at greater risk of major bleeding (MB) than AF patients without RD....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risk Factors of Gastrointestinal Bleeding in Patients Receiving New Oral Anticoagulants

Lee JY

New oral anticoagulants (NOACs) are now widely used for the prevention and treatment of venous thrombosis, and for the prevention of stroke and systemic embolism in patients with atrial fibrillation....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice

Seiffge DJ, Traenka C, Polymeris , Thilemann , Wagner B, Hert L, Müller MD, Gensicke H, Peters N, Nickel CH, Stippich C, Sutter R, Marsch S, Fisch U, Guzman R, De Marchis GM, Lyrer PA, Bonati LH, Tsakiris D, Engelter S

BACKGROUND AND PURPOSE: Standard operating procedures (SOP) incorporating plasma levels of rivaroxaban might be helpful in selecting patients with acute ischemic stroke taking rivaroxaban suitable for IVthrombolysis (IVT) or endovascular...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of Novel Oral Anticoagulant to Treat Pulmonary Thromboembolism in Patient with Ulcerative Colitis Superinfected Cytomegalovirus Colitis

Kim SH, Jang S, Sung Y, Park JK, Park Y, Yun J, Kang SB

Crohn's disease and ulcerative colitis are the two major types of inflammatory bowel disease, and affect mainly the gastrointestinal tract but also have extraintestinal sequelae, such as arterial and venous...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Delayed bleeding after implant surgery in patients taking novel oral anticoagulants: a case report

Kim C, Dam C, Jeong J, Kwak EJ, Park W

The use of novel oral anticoagulants (NOACs) has increased in recent times in an effort to overcome the shortcomings of warfarin. They are being used primarily for the prevention of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rivaroxaban for Thromboprophylaxis in Patients with Antiphospholipid Syndrome

Park JH, Song JS, Choi ST

The main treatment for Antiphospholipid syndrome (APS) is long-term anticoagulation with an oral vitamin K antagonist, although these are associated with numerous problems. Rivaroxaban is a direct anti-factor Xa inhibitor,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Multiple Intracranial Hemorrhage Following Intravenous Recombinant Plasminogen Activator in the Patients Taking Rivaroxaban

Ryu JC, Kwon JH, Choi SH, Kim WJ

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Practice Preferences on Dabigatran and Rivaroxaban for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation

Park YK, Kang JE, Kim SJ, La HO, Rhie SJ

OBJECTIVE: Prescription rate of dabigatran and rivaroxaban, which are the direct oral anticoagulants (DOAC), has increased. We have analyzed the prescription trend and medication use of dabigatran and rivaroxaban in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparisons of Bleeding Risks between Rivaroxaban and Dalteparin for Treatment of Venous Thromboembolism in Cancer Patients

Kim YK, An SH, Kim JY, Chung JE, Gwak HS

BACKGROUND: Venous thromboembolism (VTE) is a common and life-threating condition in cancer patients. Low molecular weight heparins (LMWH), such as dalteparin, are recommended in the treatment of VTE. Also, rivaroxaban,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr